Display options
Share it on

J Biol Regul Homeost Agents. 2015 Apr-Jun;29(2):137-41.

β2-AGONISTS IN CHILDHOOD ASTHMA.

Journal of biological regulators and homeostatic agents

M Miraglia Del Giudice, G Campana, F Galdo, D De Vivo, C Cuppari, A Coronella, N Maiello

Affiliations

  1. Department of Women, Child and General and Special Surgery, Second University of Naples, Italy.
  2. Department of Pediatric Sciences, Unit of Pediatrics Genetics and Immunology University of Messina, Italy.

PMID: 26634602

Abstract

β2-agonists reduce airflow limitation by improving airway diameter as a consequence of a direct action on airway smooth muscle. β;2-agonists can be broadly classified according to their duration of action: short-acting β2-agonists (SABAs), including albuterol, terbutaline and fenoterol, have pharmacodynamics half–lives between 2 and 6 h and long-acting β2-agonists (LABAs), including salmeterol and formoterol, require twice daily treatment. SABAs are often used “as needed” for asthma exacerbations and before exercise in the presence of exercise-induced bronchospasm. LABAs provide longer symptom control, which is a particularly useful feature for preventing night-time symptoms. There are two main LABAs, salmeterol and formoterol. This review focused on the recent data published on this topic.

Publication Types